Faculty

Bruce L. Levine, Ph.D.

Barbara and Edward Netter Professor in Cancer Gene Therapy

Department: Pathology and Laboratory Medicine

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Center for Cellular Immunotherapies
Smilow 8-114
3400 Civic Center Boulevard
Philadelphia, PA 19104

Office: 215-746-1481

Email:
levinebl@pennmedicine.upenn.edu

Education:
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.

Links
Clinical Cell and Vaccine Production Facility, Bruce Levine, Ph.D., Founding Director

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Research Expertise

Immunology, Cell and Gene Therapy

Description of Other Expertise

Good Manufacturing Practices

Selected Publications

Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL.: Phase I study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Mol Ther Jan 2026.

Rommel PC, Engel NW, Malachowski JK, Shukla D, Hodson IR, Gonzales D, van der Loo JCM, Young RM, Riley JL, Levine BL, June CH.: Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations. J Immunother Cancer 14: e012318, Jan 2026.

Tebas P, Jadlowsky JK, Zhou Y, Pampena MB, Leslie GJ, Liu N, Srivatsa S, Maldini CR, Wang J, Tsang CJ, Mohamed O, Romano J, Haggarty B, Plesa G, Gaymon AL, Brennan AL, Veloso E, Levine BL, Putt ME, Kulikovskaya I, Gonzalez V, Fraietta JA, Betts MR, Hoxie JA, Riley JL.: Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor. Mol Ther Jan 2026.

Ramírez-Fernández Á, Dimitri AJ, Chen F, Bartoszek R, Chen GM, Córdoba-Espejo L, Zhou Y, Tang YH, Lin CT, Acosta R, Scholler J, Ghilardi G, Porazzi P, Pellicer M, Profitós-Pelejà N, Barta SK, Chew A, Jadlowsky JK, Gonzalez VE, Siegel DL, Levine BL, Roué G, Ruella M, Lotze MT, June CH, Riley JL, Fraietta JA.: CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy. Nat Biomed Eng Oct 2025.

Golinelli G, Scholler J, Roussel-Gervais A, Šakić A, Ilmjärv S, Song D, Gabunia K, Ji M, Fan TJ, Gupta A, Deshmukh M, Berjis A, Cuoghi Costantini R, Apodaca K, Sheppard NC, Kili S, Dominici M, Alessandrini M, June CH, Levine BL.: Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. Front Immunol 16: 1647433, Aug 2025.

Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH.: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med 392: 1824-1835, May 2025.

Obiozor CC, Day LW, Dube B, Edrah IE, Uzoka E, June CH, Levine BL, Sammut SM: Cellular gene therapy access in Africa: a multifactorial feasibility analysis for implementation. Cytotherapy April 2025 Notes: doi: 10.1016/j.jcyt.2025.04.056.

Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature Medicine 31(4): 1134-1144, April 2025.

Dimitri AJ, Baxter AE, Chen GM, Hopkins CR, Rouin GT, Huang H, Kong W, Holliday CH, Wiebking V, Bartoszek R, Drury S, Dalton K, Koucky OM, Chen Z, Giles JR, Dils AT, Jung IY, O'Connor R, Collins S, Everett JK, Amses K, Sherrill-Mix S, Chandra A, Goldman N, Vahedi G, Jadlowsky JK, Young RM, Melenhorst JJ, Maude SL, Levine BL, Frey NV, Berger SL, Grupp SA, Porter DL, Herbst F, Porteus MH, Carty SA, Bushman FD, Weber EW, Wherry EJ, Jordan MS, Fraietta JA.: TET2 regulates early and late transitions in exhausted CD8(+) T cell differentiation and limits CAR T cell function. Sci Adv 10: eadp9371, Nov 2024.

Pablo Tebas, Julie K Jadlowsky, Pamela A Shaw, Lifeng Tian, Erin Esparza, Andrea L Brennan, Sukyung Kim, Soe Yu Naing, Max W Richardson, Ashley N Vogel, Colby R Maldini, Hong Kong, Xiaojun Liu, Simon F Lacey, Anya M Bauer, Felicity Mampe, Lee P Richman, Gary Lee, Dale Ando, Bruce L Levine, David L Porter, Yangbing Zhao, Don L Siegel, Katharine J Bar, Carl H June, James L Riley: CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation 134(9): e181576, May 2024.